-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the SOLO1/GOG 3004 trial, maintenance therapy with the poly (ADP-ribose) polymerase inhibitor olaparib provides a sustained progression-free survival benefit
In this double-blind, phase 3 clinical trial, newly diagnosed patients with advanced ovarian cancer who responded to platinum-based chemotherapy with BRCA mutations were randomly assigned to the olaparib group (n=260) or placebo group (n=131) for maintenance for up to 2 years
As of July 2022, 149 of the 391 patients have died
At year 7, 67.
Taken together, the findings suggest that in newly diagnosed patients with advanced ovarian cancer with BRCA mutations, olaparib maintenance therapy improves overall survival prognosis and has clinical significance, although there is no statistical significance according to predetermined criteria; Support these patients with olaparib maintenance therapy for long-term remission
Original Source:
Paul DiSilvestro, et al.